Glioblastoma-Multiforme-GBM-Epidemiology-Patient-Population-Medical-Practices-Forecasted-Epidemiology

DelveInsight’s ‘Glioblastoma Multiforme (GBM) Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Glioblastoma Multiforme (GBM) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The epidemiology report gives a thorough understanding of the disease symptoms and causes, as well as the risk factors, diagnosis, pathophysiology associated with the disease, and treatment guidelines for Glioblastoma Multiforme (GBM) in 7MM. The report provides epidemiology of GBM segmented by total diagnosed incident cases, age, gender, type-specific diagnosed incident cases, diagnosed incident population-based on primary site of GBM, and diagnosed incident population based on the histologic classification of GBM.

Request for Sample @ Glioblastoma Multiforme (GBM) Epidemiology Forecast 

Key Highlights of the Glioblastoma Multiforme (GBM) Epidemiology Report

  • According to the American Brain Tumor Association, an estimated 24,790 new cases of primary malignant brain tumors are expected to be diagnosed in the US in 2016. About 50% of gliomas are glioblastomas with 12,120 new cases predicted. They are most common in adults aged 45–65,
  • As per DelveInsight, the total diagnosed incident population of GBM in the 7 major markets was 29,440 in 2020.
  • In the United States, the diagnosed incident cases were found to be 15,426 in 2020.
  • The total diagnosed incident cases of GBM were maximum in males as compared to females in the 7 MM during the study period of 2018–2030.
  • Among the EU5 countries, the diagnosed incident population of GBM was found to be maximum in Germany with 2,945 cases followed by France in 2020. While Spain accounted for the lowest diagnosed incident population in 2020.
  • Similarly, Japan accounted for 1,950 diagnosed incident cases of GBM in 2020.

Visit to get a more detailed insight into the patient pool @ Glioblastoma Multiforme (GBM) Epidemiology and Patient Population

Glioblastoma Multiforme (GBM) Disease Overview 

Glioblastoma, also known as glioblastoma multiforme, is the most frequently occurring type of primary tumor that affects the brain or spinal cord. According to the American Association of Neurological Surgeons, GBM has an incidence of 2–3 per 100,000 adults per year and accounts for 52% of all primary brain tumors. Overall, GBM accounts for about 17% of all tumors of the brain (primary and metastatic). These tumors tend to occur in adults between the ages of 45 and 70 and are more common in men than women.

It is a quite aggressive tumor and mostly affects adults. As of now, there is no cure for Glioblastoma. Over the past few years, innovative diagnostic strategies and new therapies have been developed. However, the available treatment options only help to ease the symptoms. It is observed that the median survival time for patients with GBM is only 14.6 months.

Glioblastoma Multiforme (GBM) Epidemiology Segmentation 

  • Total Diagnosed Incident Population of Glioblastoma
  • Gender-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM)
  • Age-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM) 
  • Type-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM) 
  • Diagnosed Incident Population-based on Primary Site of Glioblastoma Multiforme (GBM) 
  • Diagnosed Incident Population-based on Histologic Classification of Glioblastoma Multiforme (GBM) 

Dive deeper to know more @ Glioblastoma Multiforme (GBM) Epidemiology Analysis

Scope of the Report

  • Detailed segmentation of the Glioblastoma Multiforme (GBM) epidemiology. 
  • A historical and forecasted patient pool of Glioblastoma Multiforme (GBM) in 7MM.
  • Assessment of the growth opportunities in the 7MM with respect to the patient population.
  • Detailed analysis of Glioblastoma Multiforme (GBM) symptoms, causes, diagnosis, classification, pathophysiology, and its treatment patterns.
  • A comprehensive evaluation of the disease in terms of its burden, and the unmet needs.
  • Overview of the risk factors and trends of Glioblastoma Multiforme (GBM) in 7MM.

Check out for more @ Glioblastoma Multiforme (GBM) Epidemiology 

Table of Contents 

1 Key Insights 
2 Glioblastoma Multiforme (GBM): Overview at a Glance
3 Executive Summary of Glioblastoma Multiforme (GBM)
4 Disease Background and Overview: Glioblastoma Multiforme (GBM)
5 Glioblastoma Multiforme (GBM): Epidemiology and Patient Population
6 Glioblastoma Multiforme (GBM): Country Wise-Epidemiology 
7 Appendix
8 DelveInsight Capabilities
9 Disclaimer
10 About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Key Highlight of the Reports 

  • Geographies Covered
    • The United States
    • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
    • Japan
  • Study Period: 2018–2030
  • Key Assessments 
    • Patient Segmentation
    • Disease Risk and Burden
    • Risk of disease by the segmentation
    • Factors driving growth in a specific patient population

Got queries? Reach out for more information @ Glioblastoma Multiforme (GBM) Epidemiology Report

Related Reports 

Glioblastoma multiforme (GBM) Market Insight
DelveInsight’s “Glioblastoma multiforme (GBM) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Glioblastoma multiforme (GBM) market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Glioblastoma multiforme (GBM) Pipeline Insights
Glioblastoma multiforme (GBM) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Glioblastoma multiforme (GBM) market.

Anti-hypertension Market Insight
DelveInsight’s “Anti-hypertension Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Anti-hypertension market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Amebiasis Market Insight
DelveInsight’s “Amebiasis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Amebiasis market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Bevacizumab Biosimilars Insight
DelveInsight’s, “Bevacizumab Biosimilar Insight, 2020,” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in Bevacizumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Ulcerative Colitis (UC) Market Insight
DelveInsight’s “Ulcerative Colitis (UC) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Ulcerative Colitis (UC) market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Traumatic Brain Injury Market Insight
DelveInsight’s “Traumatic Brain Injury Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Traumatic Brain Injury market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Latest Healthcare Blog

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Connect With Us at:
LinkedIn | Facebook | Twitter 

Tags: Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme (GBM), GBM

Contact Information:

Shruti Thakur
info@delveinsight.com
+91-9650213330